These effects may be beneficial in the context of obesity-induced inflammation, but it still remains unclear if targeting PPARβ/δ improves the classical strategy (diet, exercise) for obesity-associated risk reduction. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.